Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03270527
Other study ID # RN0307A
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2017
Est. completion date July 31, 2019

Study information

Verified date October 2021
Source University of Surrey
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Raised blood cholesterol (also referred to as blood LDL-cholesterol) is a major risk factor for developing heart disease. Dietary saturated fat is recognised as the main dietary component responsible for raising blood LDL-cholesterol, and reducing its intake has been the mainstay of dietary guidelines for the prevention of heart disease for over 30 years. However, there is very little evidence for a direct link between the intake of saturated fat and risk of dying from heart disease. One explanation for this, is that the link between saturated fat intake and heart disease is not a direct one, but relies heavily on the ability of saturated fat to raise blood LDL-cholesterol levels. This LDL cholesterol-raising effect of saturated fat is complex, and highly variable between individuals because of differences in the metabolism of dietary fat and cholesterol between people. The main aim of this study is to measure the amount of variation in blood LDL-cholesterol in healthy volunteers at the Universities of Surrey and Reading in response to lowering the amount of saturated fat in the diet to the level recommended by the government for the prevention of heart disease. This collaborative project between the Universities of Reading, Surrey and Imperial ('RISSCI-1' Blood Cholesterol Response Study') will permit identification of two subgroups of men who show either a high or low LDL-cholesterol response to a reduction in dietary saturated intake. These two groups of participants will be provided with an opportunity to participate in a similar follow-up study ('RISSCI-2') that will also take place at the University of Surrey and Reading. In this follow-up study, the participants will be asked to repeat a similar study protocol as for RISSCI-1, but undergo more detailed measurements to investigate the metabolic and genetic origins of how saturated fat is metabolised in the body and influences blood LDL-cholesterol (LDL-C).


Description:

The LDL cholesterol-raising effect of saturated fatty acids (SFA) is complex, and highly variable between individuals because of differences in the metabolism of dietary fat and blood cholesterol between people. While these differences in metabolism make it difficult to study how dietary SFA influences LDL-cholesterol in large numbers of people, they can be measured in the laboratory and used as biological markers to distinguish between people who respond well from those who will respond less well to moderate-fat diets, which are lower in SFA. The main aim of this study is to measure the amount of variation in blood LDL-cholesterol in healthy male volunteers in response to the replacement of SFA with unsaturated fats, and to select LDL-C responders from non-responders for a subsequent metabolic study ('RISSC-2'). Estimate of statistical power and sample size for 'RISSCI-1': A decrease of 0.16 mmol/L (SD 0.54) in our primary outcome of fasting plasma LDL-C between the high- and low-SFA diets, as observed in a previous randomly controlled trial, will require a sample size of 92 participants, at 80% power and 5% significance level. An estimated attrition rate of 15% will increase this sample size to 106 participants. To recruit this sample of participants, we anticipate having to screen 150 volunteers (75 at each site). Specific objectives: 1. Undertake a dietary intervention study to examine the effects of two, 4 week diets that differ in their composition of fatty acids. The first diet ('Diet 1') will contain ~18% of its total energy as saturated fatty acids (SFA), while the second diet ('Diet 2') will contain ~10% of its total energy as SFA. Blood, urine and stool samples taken at the beginning (week 0) and end of Diet 1 (week 4), and end of Diet 2 (week 8), will be analysed to measure blood LDL-cholesterol and other relevant blood, urine and faecal metabolites. The white blood cell buffy coat will also be isolated from the blood samples collected at the baseline visit to enable genotyping of relevant genes involved in the absorption and metabolism of dietary fat. 2. To examine the data for evidence of associations between the changes in blood LDL- cholesterol, and the physical and biochemical characteristics of the participants as possible determinants of the variation in serum cholesterol response. This will include measurement of a common genetic polymorphism in APOLIPOPROTEIN E, as an established determinant of variation in blood cholesterol in response to dietary SFA. 3. To identify two subgroups of individuals whose blood LDL-cholesterol either responds ('Responders') or show little or no response ('Non-responders') on changing from Diet 1 to Diet 2, for participation in the follow-up study ('RISSCI-2'), which will be conducted at the Universities of Surrey, Reading and Imperial College London. In this follow-up study, the participants will be asked to repeat a similar study protocol as for RISSCI-1, and undergo more detailed measurements to determine how saturated fat is metabolised in the body. Hypothesis: In accordance with the variation in blood LDL-cholesterol response, that many studies have reported previously following substitution of dietary saturated with unsaturated fats, the investigators hypothesise that consuming Diet 1 (a high saturated fat diet) for 4 weeks followed by diet 2 (a low saturated fat/high unsaturated fat diet) for a further 4 weeks, will: 1) produce a variable distribution of responses in LDL-cholesterol that will enable the study of associations between the participants' baseline characteristics as possible determinants of the observed variation in blood LDL-cholesterol response, and 2) identify two distinct subgroups of individuals who either respond or show little or no response in their blood LDL- cholesterol. These distinct groups will be defined by the top and bottom ~10% of change in the concentration of blood LDL-cholesterol.


Recruitment information / eligibility

Status Completed
Enrollment 109
Est. completion date July 31, 2019
Est. primary completion date July 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria: - BMI of 19-32 kg/m2 - Fasting serum total cholesterol < 7.5 mmol/l and triacylglycerol < 2.3 mmol/l Exclusion Criteria: - Smokers - Medical history of myocardial ischemia or stroke in the past 12 months; - Diabetes (defined as fasting glucose > 7.0 mmol/l) or other endocrine disorders; kidney, liver, pancreas or gastrointestinal disorders - Hypertension (blood pressure > 140/90 mmHg), - Cancer - Medication for hyperlipidaemia (e.g. statins), hypertension, inflammation or prescribed antibiotics within the last three months - Drinking in excess of 14 units of alcohol per week, - Anaemia (<130 g/L haemoglobin), or planning on a weight-reducing regime - Taking any dietary supplements known to influence lipids/gut microbiota (eg. plant stanols, fish oil, phytochemicals, natural laxatives, probiotics and prebiotics) - Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High SFA diet (Diet 1)
'Diet 1' will contain ~18% of its total energy as SFA .
Low SFA diet (Diet 2)
'Diet 2' will contain ~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.

Locations

Country Name City State
United Kingdom Department of Nutritional Sciences, University of Surrey Guildford Surrey
United Kingdom Department of Food and Nutritional Sciences, University of Reading Reading Berkshire

Sponsors (3)

Lead Sponsor Collaborator
University of Surrey Imperial College London, University of Reading

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Vafeiadou K, Weech M, Altowaijri H, Todd S, Yaqoob P, Jackson KG, Lovegrove JA. Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. Am J Clin Nutr. 2015 Jul;102(1):40-8. doi: 10.3945/ajcn.114.097089. Epub 2015 May 27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Genotyping for apolipoprotein E to determine the impact of this genotype on changes in the primary and secondary outcome measurements in response to dietary fat intake Baseline
Primary Changes in fasting total cholesterol (consisting of LDL-cholesterol and HDL) concentrations Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Fasting triacylglycerol Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary HDL immune functions Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary HDL anti-inflammatory and anti-oxidant (PON-1) properties Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary HDL capacity to promote cholesterol efflux (ex-vivo) Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Fasting insulin, glucose Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Adhesion molecules, markers of vascular function Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Inflammatory markers & adipokines Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary LDL-R gene expression Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Other relevant genes involved in the absorption and metabolism of dietary fat Polymorphic genes with potential influence on the serum LDL response to dietary saturated fat, e.g.: ATP-binding cassette proteins (cholesterol efflux proteins) ABCG5 (e.g. C1950G) ABCG8 (e.g. D19H, C1895T), functional polymorphisms in the farnesoid X receptor (FXR) and bile acid transporters (e.g. solute carrier organics anion 1B1). Fatty acid desaturases (FADS1 and FADS2). The patatin-like phospholipase domain-containing protein (PNPLA3) (e.g. rs738409 C/G), eNOS. Lipid/cholesterol homeostasis: serum apolipoprotein genes: APOE (e2,e3,e4 e.g. rs429358 and rs7412), APOA-I (e.g. -75G/A), APOA4 (e.g. 360-2), APOA5 (e.g. -113/T>:c), APOCIII, APOB (e.g. -516C/T). Lipase genes: (e.g. LPL, HL, MGLL). Lipoprotein receptor genes (e.g. pvu11 in the LDL receptor), lipid transfer proteins (e.g. CETP e.g Taq1B, MTP), and other polymorphic genes related to the absorption and metabolism of dietary fat and regulation of lipid/cholesterol homeostasis. Baseline
Secondary Metabolomic analysis for the determination of the low molecular weight metabolite profiles in the biological fluids Analyses conducted by Imperial College London Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Changes in faecal bacterial population Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Weight BMI will also be calculated (kg/ height in m^2) Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Fat mass Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Fat free mass Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Waist circumference Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Hip circumference Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Blood pressure Baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
Secondary Fasting vascular stiffness Measured via pulse wave assessment using the Mobil-O-graph device. baseline, 4 weeks (after diet 1), 8 weeks (after diet 2)
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1